Kilitch Drugs' Q1 Financial Report Shows Significant Decline, Receives 'Strong Sell' Rating

Aug 09 2024 10:31 AM IST
share
Share Via
Kilitch Drugs (India) has reported a significant decline in its financial performance for the quarter ending March 2024. The company's score has fallen from 2 to -22, with a decrease in PBT, PAT, and Net Sales. Interest costs have also risen, indicating increased borrowings. The company's operating profit margin has decreased, and its income from non-business activities is high. Investors are advised to exercise caution while considering this stock.

Kilitch Drugs (India), a microcap pharmaceutical company, recently declared its financial results for the quarter ending March 2024. The stock has been given a 'Strong Sell' call by MarketsMOJO, indicating a negative outlook for the company.

According to the financial report, Kilitch Drugs has seen a significant decline in its financial performance in the last quarter. The company's score has fallen from 2 to -22 in the last 3 months, indicating a very negative trend.

Some key areas that have contributed to this decline include a decrease in Profit Before Tax (PBT) and Profit After Tax (PAT), as well as a decrease in Net Sales. The company's PBT has fallen by 124.6% compared to the average of the previous four quarters, while PAT has fallen by 63.3%. This trend is expected to continue in the near term.

Additionally, Kilitch Drugs has seen a rise in its interest costs, which signifies increased borrowings. The company's ability to manage these interest payments has also deteriorated, with the Operating Profit to Interest ratio being at its lowest in the last five quarters.

The company's operating profit margin has also decreased, indicating a decline in efficiency. Furthermore, the company's income from non-business activities is high, which is not a sustainable business model.

Overall, Kilitch Drugs' financial performance for the quarter ending March 2024 has been very negative, with declining profitability and a high debt-equity ratio. Investors are advised to exercise caution while considering this stock.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
Kanani Industries Ltd is Rated Strong Sell
41 minutes ago
share
Share Via
Shiva Texyarn Ltd is Rated Sell
41 minutes ago
share
Share Via
Riba Textiles Ltd is Rated Sell
41 minutes ago
share
Share Via
Piramal Pharma Ltd is Rated Strong Sell
41 minutes ago
share
Share Via
Infibeam Avenues Ltd is Rated Hold
41 minutes ago
share
Share Via